This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

StemCells, Inc. Strengthens Senior Executive Team

NEWARK, Calif., June 17, 2014 (GLOBE NEWSWIRE) -- StemCells, Inc. (Nasdaq:STEM) announced today one promotion and three new appointments to the Company's executive team. Stephen Huhn, M.D., F.A.C.S., F.A.A.P. has been promoted to the newly created position of vice president, CNS clinical research and chief medical officer. Joel Naor, M.D., M.B.A., M.Sc., has joined StemCells, Inc. as vice president, clinical development, ophthalmology, and will report to Dr. Stephen Huhn; Naymisha Patel has joined StemCells, Inc. as vice president, quality systems; and Mohammad A. El-Kalay, Ph.D. has joined StemCells, Inc. as vice president, process development. Dr. Huhn, Ms. Patel and Dr. El-Kalay will report to Martin McGlynn president and chief executive officer of StemCells, Inc.

"We are pleased to welcome Dr. Naor, Ms. Patel and Dr. El-Kalay to StemCells, Inc., and Dr. Huhn to his new position, at this critical point in the Company's evolution," said Martin McGlynn. "We plan to initiate our first controlled Phase II studies in spinal cord injury and dry age related macular degeneration (AMD) this year. Dr. Huhn's combined background in neurosurgery and academic research, together with his demonstrated leadership of our clinical activities, have prepared him well to assume his new role as our chief medical officer. Dr. Naor's 14 years of clinical experience, with a focus on eye related disorders, will be instrumental for the success of our dry AMD program. Ms. Patel's experience in building and leading quality organizations and Dr. El-Kalay's operational management and process development experience will be invaluable as we look beyond the planned Phase II studies towards additional pivotal studies and the commercialization phase."

As chief medical officer, Dr. Huhn will continue to oversee all aspects of the Company's clinical activities. Dr. Huhn joined StemCells, Inc. in January 2007 to direct the Company's preclinical and clinical development programs for CNS indications. Prior to joining the company, he was associate professor of neurosurgery at Stanford University and chief of pediatric neurosurgery at the Lucile Salter Packard Children's Hospital. Dr. Huhn earned his M.D. at the University of Arizona in 1987 and completed a residency in neurosurgery at the University of Maryland in 1993. He completed a fellowship in neuro-oncology at UCSF Medical Center in San Francisco and pediatric neurosurgery at Northwestern University's Children's Memorial Hospital in Chicago. Dr. Huhn is certified by the American Board of Neurological Surgery and the American Board of Pediatric Neurological Surgery and is a fellow in the American College of Surgeons and the American Academy of Pediatrics. Dr. Huhn maintains an unpaid consulting associate professor appointment with the department of neurosurgery at Stanford University.

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG

Markets

Chart of I:DJI
DOW 16,069.51 -305.25 -1.86%
S&P 500 1,916.36 -34.77 -1.78%
NASDAQ 4,670.1420 -63.3550 -1.34%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs